Mandate

Vinge advises Calliditas

Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasdaq Global Select Market in United States.

The trading on The Nasdaq Global Select Market in United States began on 5 June 2020. The total value of the global offering amounts to approximately USD 103.5 million, assuming that the over allotment option is fully exercised.

Calliditas is a specialty pharmaceutical company, focused on the development and commercialization of the product candidate Nefecon, intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin, Hampus Olsson and Julia Hirschberg.

Related

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025

Vinge has advised Eleda in connection with its acquisition of Rail Solutions Scandinavia AB, Gridtec AB, Quantity Surveying Konsult Stockholm AB, Voene AB, Vägservice centralen i Norden AB and Frästech AB.

Vinge has advised the leading infrastructure group Eleda in connection with its parallel acquisitions of Rail Solutions Scandinavia (railway maintenance), Gridtec (engineering consultancy in electric power), Quantity Surveying Konsult Stockholm (cost control and project management), Voene (traffic safety), Vägservice centralen i Norden and Frästech (road and bridge maintenance). The acquired businesses had a strong profitability with a combined turnover of approximately 200 MSEK in 2024.
June 04, 2025